LMNL — Liminal BioSciences Income Statement
0.000.00%
HealthcareSpeculativeMicro Cap
- $27.62m
- $14.21m
- CA$0.40m
Annual income statement for Liminal BioSciences, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
R2018 December 31st | R2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 24.6 | 0.745 | 0.724 | 0.643 | 0.401 |
Cost of Revenue | |||||
Gross Profit | -1.07 | — | — | — | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 256 | 147 | 47.9 | 50.5 | 33.4 |
Operating Profit | -232 | -146 | -47.2 | -49.9 | -33 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -259 | -151 | -49.2 | -44.9 | -29.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | -240 | -151 | -49 | -45.1 | -28.9 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -195 | -206 | -118 | 12.9 | 0.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -195 | -206 | -118 | 12.9 | 0.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1,470 | -55.7 | -20.2 | -14.9 | -9.34 |